Home » SYSMEX DEVELOPS TECHNOLOGY TO DIAGNOSE THE RISK OF POSTOPERATIVE RECURRENCE OF EARLY-STAGE CANCER
SYSMEX DEVELOPS TECHNOLOGY TO DIAGNOSE THE RISK OF POSTOPERATIVE RECURRENCE OF EARLY-STAGE CANCER
Sysmex announced the development of a new technology based on a cell cycle profiling for diagnosis of the risk of recurrence in patients with early-stage cancer. In a clinical study of roughly 200 cases conducted in collaboration with Shinzaburo Noguchi, Graduate School of Medicine, Osaka University, this technology was found to be a high degree of clinical usefulness in patients with early stages of breast cancer.
Japan Corporate News (http://japancorp.net/Article.Asp?Art_ID=9176)
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
18Jul
-
21Oct